Trial: Study of Chemotherapy Plus Ipatasertib …

Trial Details

Sponsor: National Cancer Institute (NCI) (federal)

Phase: 2

Start date: Sept. 22, 2023

Planned enrollment: 33

Show Summary from Sponsor

This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.

More details:

PRIMARY OBJECTIVE: I. To assess the overall response rate (ORR) (confirmed and unconfirmed, complete, and partial) with the combination of paclitaxel plus ipatasertib in participants with advanced PTEN/AKT-altered non-breast solid tumors who have previously progressed on taxane-based therapy SECONDARY OBJECTIVES: I. To assess the progression-free survival (PFS) in the study population. II. To assess the duration of response (DoR) in participants who respond to treatment. III. To assess the overall survival (OS) in the study population. IV. To evaluate the frequency and severity of toxicities related to the combination therapy. V. Collect tissue and provide it to the ComboMATCH Registration protocol to assess concordance between the diagnostic tumor mutation profile generated by the designated laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor deoxyribonucleic acid (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration protocol. For this treatment substudy, the outcome objective will be to report the proportion of cases providing sufficient tissue for that integrated scientific activity in the ComboMATCH Registration protocol. TRANSLATIONAL MEDICINE OBJECTIVES: I. To conduct whole exome sequencing (WES) and ribonucleic acid (RNA) sequencing (RNAseq) analysis of tumors at baseline (mandatory), as well as PTEN expression analysis of tumors at baseline (2nd priority after nucleic acid for WES and RNAseq). II. To explore changes in plasma PTEN/AKT mutation allelic burden and other molecular findings at baseline (mandatory) and upon progression (optional) using ctDNA and correlate changes with response/resistance to therapy. III. To perform comprehensive protein expression and function analysis on fresh frozen specimens (optional) collected at baseline and at progression to assess determinants of response and resistance to therapy. OUTLINE: Patients receive paclitaxel intravenously (IV) on days 1, 8, and 15 and ipatasertib orally (PO) on days 1-21 of each cycle. Treatment repeats every 28 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a computed tomography (CT) or magnetic resonance imaging (MRI) and blood collection throughout the trial. Patients also undergo a tumor biopsy during screening and optionally during follow-up. After completion of study treatment, patients are followed until death or 3 years after registration, whichever occurs first.

Investigational Drug AI Analysis

Show for: Ipatasertib (RG7440, GDC-0068)

More Resources

Trial ID: NCT05554380

More trial details at ClinicalTrials.gov

Show News & AI Analysis

HealthScout AI Analysis

Goal: To evaluate the efficacy of combining paclitaxel with ipatasertib in patients with advanced, unresectable, or metastatic non-breast solid tumors harboring PTEN or AKT alterations who are refractory to taxane chemotherapy.

Patients: Adults with histologically confirmed, advanced or metastatic non-breast solid tumors with activating PTEN or AKT alterations and who have progressed on or within 6 months of prior taxane-based therapy. Patients must have measurable disease and adequate organ function, and must not have received prior AKT inhibitors.

Design: This is a single-arm, non-randomized, phase II treatment trial enrolling approximately 33 participants. All participants will receive the investigational combination therapy. Mandatory pre-treatment tumor biopsy or recent archival tissue is required.

Treatments: Participants receive paclitaxel IV on days 1, 8, and 15 of each 28-day cycle, combined with oral ipatasertib on days 1-21 of each cycle, for up to 35 cycles. Ipatasertib is an oral, selective pan-AKT inhibitor that targets AKT1, AKT2, and AKT3; it has shown improved progression-free survival when combined with abiraterone in metastatic prostate cancer with PTEN loss, and has been previously studied in combination with paclitaxel in triple-negative breast cancer. The standard chemotherapy agent, paclitaxel, disrupts microtubule dynamics leading to tumor cell death.

Outcomes: The primary endpoint is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), and duration of response (DoR). Safety and toxicity profiles will also be assessed. Translational objectives include correlative studies with tissue, ctDNA, and molecular analyses.

Burden on patient: The burden on patients is moderate. In addition to standard requirements for frequent clinic visits for IV chemotherapy and monitoring, mandatory pre-treatment tumor biopsy or submission of recent archival tissue is required, with an optional follow-up biopsy. Regular imaging (CT or MRI) and blood draws for laboratory and correlative studies are required as per protocol. The oral investigational drug (ipatasertib) and IV chemotherapy (paclitaxel) require adherence to dosing schedules and monitoring for toxicity, but the schedule and procedures are similar to other early-phase combination therapy trials.

Eligibility

Show Criteria

Inclusion Criteria:

* Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-S3 based on the presence of an actionable mutation as defined in EAY191

* GENERAL COMBOMATCH EAY191 REGISTRATION INCLUSION CRITERIA:

* Participants must be enrolled on the ComboMATCH Master Registration Trial EAY191

* Participants must have an activating AKT mutation (a known mutation in AKT1, AKT2, or AKT3, a single nucleotide variant, insertion, or deletion), PTEN mutation (a known mutation in PTEN, a single nucleotide variant, insertion, or deletion), or genomic deletion loss of PTEN as determined by the ComboMATCH screening assessment

* GENERAL COMBOMATCH EAY191 REGISTRATION EXCLUSION CRITERIA:

* Participants must not have an activating KRAS, NRAS, HRAS, or BRAF mutation (a single nucleotide variant, insertion, or deletion) as determined by the ComboMATCH screening assessment

* Participants must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191)

* Participants must have a histologically confirmed non-breast solid malignancy

* Participants must have locally advanced, unresectable, or metastatic disease in the opinion of the treating investigator

* Participants must have measurable disease documented by CT or MRI. Measurable disease must be assessed within 28 days prior to registration. Non-measurable disease must be assessed within 42 days prior to registration. The CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1). Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration

* Participants with known brain metastases must have a CT/MRI scan to evaluate for central nervous system (CNS) disease and show no evidence of progression within 42 days prior to registration

* Participants must have completed any CNS-directed therapy and/or local therapy for spinal cord compression at least 28 days prior to registration

* Participants must not have spinal cord compression or brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days prior to registration, AND (2) participant has no residual neurological dysfunction and has been off corticosteroids for at least 24 hours prior to registration

* Participants must not have leptomeningeal disease

* Participants must have progressed on or within 6 months of taxane-based therapy in the neoadjuvant/adjuvant or metastatic setting prior to registration

* Participants must not have received any prior AKT inhibitor (e.g., capivasertib or ipatasertib); prior PI3K/mTOR inhibitor is acceptable

* Participants must not have received cancer-directed therapy prior for at least 14 days prior to initiation of treatment on study

* Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic, radiation, or hormonal therapy for cancer treatment while receiving treatment on this study

* Participants must be \>= 18 years of age

* Participants must be able to swallow oral medications whole

* Participants must have a pre-study history and physical exam done within 28 days prior to registration

* Participants must have a Zubrod performance status of 0-2 within 28 days prior to registration

* Participants must have adverse events resolved =\< grade 1 related to any prior therapy, except alopecia within 14 days prior to registration

* Participants with neuropathy must have resolved to \< grade 2 within 14 days prior to registration

* Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to registration)

* Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to registration)

* Platelets \>= 100 x 10\^3/uL (within 28 days prior to registration)

* Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration)

* Aspartate aminotransferase (AST) \& alanine aminotransferase (ALT) =\< 3 x institutional ULN (within 28 days prior to registration)

* Participants must have adequate cardiac function, class IIB (2B) or better. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification

* Participants must have a measured OR calculated creatinine clearance \>= 50 mL/min using the following Cockcroft-Gault formula. This specimen must have been drawn within 28 days prior to registration

* Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test on the most recent test results obtained within 6 months prior to registration

* Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on suppressive therapy within 28 days prior to registration

* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration

* Participants must have an electrocardiography (ECG) performed (if clinically indicated with a corrected QTc interval of =\< 470 msec) within 28 days prior to registration

* Participants must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipatasertib and/or paclitaxel

* Participants must not have an active small/large bowel inflammation such as ulcerative colitis or Crohn's disease

* Participants must not have grade 2 or higher uncontrolled intercurrent illness

* NOTE: To receive an agent, participant must not have any uncontrolled intercurrent illness requiring antibiotic/antiviral/antifungal therapy or interventional procedures. Participants with infections unlikely to be resolved within 2 weeks following registration should not be considered for the trial

* Participants must not have a known grade 2 or higher uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia

* Participants must not have any of the following:

* Cirrhosis at a level of Child-Pugh B (or worse),

* Cirrhosis (any degree) and a history of hepatic encephalopathy, or

* Clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis

* Participants must not be receiving any medications or substances that are inhibitors or inducers of CYP3A. Treatment with strong CYP3A inhibitors or strong CYP3A inducers within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug is prohibited.

* NOTE: Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product. The participant wallet card should be presented to the participant

* Participants must not have baseline fasting glucose (after 8-hour fast) \> 160 mg/dL (8.9 mmol/L) within 28 days prior to registration

* Participants with known diabetes mellitus must not require insulin therapy or have a baseline fasting glucose \>150 mg/dL (8.3 mmol/L) or high glycosylated hemoglobin (Hb)A1c, (\>= 8.0%), suggesting poorly controlled diabetes

* Participants who are on a stable dose of oral diabetes medication \>= 2 weeks prior to initiation of study drug treatment are eligible for enrollment

* Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) must not have a potential to interfere with the safety or efficacy assessment of the investigational regimen

* Participants must not have lung disease requiring active systemic therapy or placing participants at increased risk of toxicity related to study-directed therapy including, but not limited to pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)

* Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is of "reproductive potential". In addition to routine contraceptive methods, "effective contraception" also includes surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

* Participants must not have psychiatric illness/social situations that would limit compliance with study requirements

Sites (207)

Sort by distance to:

Centro Comprensivo de Cancer de UPR

San Juan, 00927, Puerto Rico

[email protected] / 888-823-5923

Status: Recruiting

Puerto Rico Hematology Oncology Group

Bayamon, 00961, Puerto Rico

No email / 787-780-2865

Status: Recruiting

University of South Alabama Mitchell Cancer Institute

Mobile, Alabama, 36688, United States

[email protected] / 251-445-9870

Status: Recruiting

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States

[email protected] / 205-934-0220

Status: Recruiting

Alaska Women's Cancer Care

Anchorage, Alaska, 99508, United States

[email protected] / 907-212-6871

Status: Recruiting

Kingman Regional Medical Center

Kingman, Arizona, 86401, United States

[email protected] / 702-384-0013

Status: Recruiting

Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304, United States

[email protected] / 650-498-7061

Status: Recruiting

Saint John's Cancer Institute

Santa Monica, California, 90404, United States

No email / 310-582-7448

Status: Recruiting

PCR Oncology

Arroyo Grande, California, 93420, United States

[email protected] / 702-384-0013

Status: Recruiting

Cedars Sinai Medical Center

Los Angeles, California, 90048, United States

No email / 310-423-8965

Status: Recruiting

Saint Joseph Hospital - Orange

Orange, California, 92868, United States

No email / 714-734-6220

Status: Recruiting

The Angeles Clinic and Research Institute - West Los Angeles Office

Los Angeles, California, 90025, United States

[email protected] / No phone

Status: Recruiting

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442, United States

No email / No phone

Status: Active, not recruiting

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States

No email / 855-776-0015

Status: Recruiting

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States

No email / No phone

Status: Active, not recruiting

UM Sylvester Comprehensive Cancer Center at Kendall

Miami, Florida, 33176, United States

No email / No phone

Status: Active, not recruiting

UM Sylvester Comprehensive Cancer Center at Plantation

Plantation, Florida, 33324, United States

No email / No phone

Status: Active, not recruiting

UM Sylvester Comprehensive Cancer Center at Aventura

Aventura, Florida, 33180, United States

No email / No phone

Status: Active, not recruiting

UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables, Florida, 33146, United States

No email / No phone

Status: Active, not recruiting

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814, United States

[email protected] / 406-969-6060

Status: Recruiting

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706, United States

[email protected] / 734-712-3671

Status: Recruiting

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712, United States

[email protected] / 208-381-2774

Status: Recruiting

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605, United States

No email / No phone

Status: SUSPENDED

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619, United States

[email protected] / 208-381-2774

Status: Recruiting

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642, United States

[email protected] / 208-381-2774

Status: Recruiting

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687, United States

[email protected] / 406-969-6060

Status: Recruiting

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687, United States

[email protected] / 208-381-2774

Status: Recruiting

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854, United States

[email protected] / 406-969-6060

Status: Recruiting

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864, United States

[email protected] / 406-969-6060

Status: Recruiting

Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301, United States

[email protected] / 208-381-2774

Status: Recruiting

Advocate Good Shepherd Hospital

Barrington, Illinois, 60010, United States

No email / 847-842-4847

Status: Recruiting

Advocate Illinois Masonic Medical Center

Chicago, Illinois, 60657, United States

No email / 773-296-5360

Status: Recruiting

AMG Crystal Lake - Oncology

Crystal Lake, Illinois, 60014, United States

[email protected] / 630-929-6129

Status: Recruiting

Carle at The Riverfront

Danville, Illinois, 61832, United States

[email protected] / 800-446-5532

Status: Recruiting

Advocate Good Samaritan Hospital

Downers Grove, Illinois, 60515, United States

[email protected] / 630-275-1270

Status: Recruiting

Carle Physician Group-Effingham

Effingham, Illinois, 62401, United States

[email protected] / 800-446-5532

Status: Recruiting

Advocate Sherman Hospital

Elgin, Illinois, 60123, United States

No email / 847-429-2907

Status: Recruiting

Advocate South Suburban Hospital

Hazel Crest, Illinois, 60429, United States

No email / 708-799-9995

Status: Recruiting

AMG Libertyville - Oncology

Libertyville, Illinois, 60048, United States

[email protected] / 630-929-6129

Status: Recruiting

Condell Memorial Hospital

Libertyville, Illinois, 60048, United States

[email protected] / 630-929-6129

Status: Recruiting

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938, United States

[email protected] / 800-446-5532

Status: Recruiting

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451, United States

[email protected] / 773-702-8222

Status: Recruiting

Advocate Christ Medical Center

Oak Lawn, Illinois, 60453-2699, United States

No email / 800-323-8622

Status: Recruiting

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462, United States

[email protected] / 773-702-8222

Status: Recruiting

Advocate Lutheran General Hospital

Park Ridge, Illinois, 60068, United States

No email / 847-384-3621

Status: Recruiting

Carle Cancer Center

Urbana, Illinois, 61801, United States

[email protected] / 800-446-5532

Status: Recruiting

John H Stroger Jr Hospital of Cook County

Chicago, Illinois, 60612, United States

No email / 312-864-5204

Status: Recruiting

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States

[email protected] / 773-702-8222

Status: Recruiting

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314, United States

[email protected] / 515-358-6613

Status: Recruiting

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263, United States

No email / 515-241-3305

Status: Recruiting

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023, United States

No email / 515-241-3305

Status: Recruiting

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309, United States

No email / 515-241-3305

Status: Recruiting

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States

No email / 859-257-3379

Status: Recruiting

Harold Alfond Center for Cancer Care

Augusta, Maine, 04330, United States

No email / 207-626-4855

Status: Recruiting

Lafayette Family Cancer Center-EMMC

Brewer, Maine, 04412, United States

No email / 800-987-3005

Status: Recruiting

MaineHealth Maine Medical Center- Scarborough

Scarborough, Maine, 04074, United States

[email protected] / 207-396-8670

Status: Recruiting

UPMC Western Maryland

Cumberland, Maryland, 21502, United States

No email / 240-964-1400

Status: Recruiting

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States

No email / 800-888-8823

Status: Recruiting

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

No email / 800-411-1222

Status: Recruiting

Tufts Medical Center

Boston, Massachusetts, 02111, United States

[email protected] / 617-636-5000

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health Medical Center - Canton

Canton, Michigan, 48188, United States

[email protected] / 734-712-7251

Status: Recruiting

Chelsea Hospital

Chelsea, Michigan, 48118, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118, United States

[email protected] / 734-712-7251

Status: Recruiting

Corewell Health Dearborn Hospital

Dearborn, Michigan, 48124, United States

No email / 248-551-7695

Status: Recruiting

Cancer Hematology Centers - Flint

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

Genesee Hematology Oncology PC

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

Genesys Hurley Cancer Institute

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

Hurley Medical Center

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912, United States

[email protected] / 517-364-3712

Status: Recruiting

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States

[email protected] / 734-712-7251

Status: Recruiting

Henry Ford Saint John Hospital - Macomb Medical

Macomb, Michigan, 48044, United States

[email protected] / 313-343-3166

Status: Recruiting

Corewell Health William Beaumont University Hospital

Royal Oak, Michigan, 48073, United States

No email / 248-551-7695

Status: Recruiting

MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601, United States

[email protected] / 734-712-7251

Status: Recruiting

Oncology Hematology Associates of Saginaw Valley PC

Saginaw, Michigan, 48604, United States

No email / No phone

Status: SUSPENDED

MyMichigan Medical Center Tawas

Tawas City, Michigan, 48764, United States

[email protected] / 734-712-7251

Status: Recruiting

Corewell Health Beaumont Troy Hospital

Troy, Michigan, 48085, United States

No email / 248-551-7695

Status: Recruiting

Saint Mary's Oncology/Hematology Associates of West Branch

West Branch, Michigan, 48661, United States

No email / No phone

Status: SUSPENDED

Huron Gastroenterology PC

Ypsilanti, Michigan, 48106, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197, United States

[email protected] / 734-712-7251

Status: Recruiting

Corewell Health Farmington Hills Hospital

Farmington Hills, Michigan, 48336, United States

No email / 248-551-7695

Status: Recruiting

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114, United States

[email protected] / 734-712-7251

Status: Recruiting

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601, United States

[email protected] / 218-333-5000

Status: Recruiting

Essentia Health Cancer Center

Duluth, Minnesota, 55805, United States

[email protected] / 218-786-3308

Status: Recruiting

Fairview Southdale Hospital

Edina, Minnesota, 55435, United States

[email protected] / 952-993-1517

Status: Recruiting

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746, United States

No email / 218-786-3308

Status: Recruiting

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407, United States

[email protected] / 952-993-1517

Status: Recruiting

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

No email / 855-776-0015

Status: Recruiting

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416, United States

[email protected] / 952-993-1517

Status: Recruiting

Regions Hospital

Saint Paul, Minnesota, 55101, United States

[email protected] / 952-993-1517

Status: Recruiting

United Hospital

Saint Paul, Minnesota, 55102, United States

[email protected] / 952-993-1517

Status: Recruiting

Essentia Health Sandstone

Sandstone, Minnesota, 55072, United States

[email protected] / 218-786-3308

Status: Recruiting

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792, United States

[email protected] / 218-786-3308

Status: Recruiting

Mercy Hospital

Coon Rapids, Minnesota, 55433, United States

[email protected] / 952-993-1517

Status: Recruiting

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636, United States

[email protected] / 218-786-3308

Status: Recruiting

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715, United States

[email protected] / 406-969-6060

Status: Recruiting

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405, United States

[email protected] / 406-969-6060

Status: Recruiting

Logan Health Medical Center

Kalispell, Montana, 59901, United States

No email / No phone

Status: SUSPENDED

Community Medical Center

Missoula, Montana, 59804, United States

[email protected] / 406-969-6060

Status: Recruiting

Community Hospital of Anaconda

Anaconda, Montana, 59711, United States

[email protected] / 406-969-6060

Status: Recruiting

Billings Clinic Cancer Center

Billings, Montana, 59101, United States

[email protected] / 800-996-2663

Status: Recruiting

OptumCare Cancer Care at Fort Apache

Las Vegas, Nevada, 89148, United States

[email protected] / 702-384-0013

Status: Recruiting

OptumCare Cancer Care at Seven Hills

Henderson, Nevada, 89052, United States

[email protected] / 702-384-0013

Status: Recruiting

OptumCare Cancer Care at Charleston

Las Vegas, Nevada, 89102, United States

[email protected] / 702-384-0013

Status: Recruiting

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States

No email / 732-235-7356

Status: Recruiting

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

[email protected] / 800-767-9355

Status: Recruiting

Mount Sinai Hospital

New York, New York, 10029, United States

[email protected] / 212-824-7309

Status: Recruiting

Duke University Medical Center

Durham, North Carolina, 27710, United States

No email / 888-275-3853

Status: Recruiting

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122, United States

[email protected] / 701-234-6161

Status: Recruiting

Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501, United States

[email protected] / 701-323-5760

Status: Recruiting

Sanford Broadway Medical Center

Fargo, North Dakota, 58122, United States

[email protected] / 701-323-5760

Status: Recruiting

Mount Carmel East Hospital

Columbus, Ohio, 43213, United States

[email protected] / 614-488-2745

Status: Recruiting

Columbus Oncology and Hematology Associates Inc

Columbus, Ohio, 43214, United States

[email protected] / 614-788-3860

Status: Recruiting

Riverside Methodist Hospital

Columbus, Ohio, 43214, United States

[email protected] / 614-788-3860

Status: Recruiting

Grant Medical Center

Columbus, Ohio, 43215, United States

[email protected] / 614-788-3860

Status: Recruiting

The Mark H Zangmeister Center

Columbus, Ohio, 43219, United States

[email protected] / 614-488-2745

Status: Recruiting

Doctors Hospital

Columbus, Ohio, 43228, United States

[email protected] / 614-788-3860

Status: Recruiting

Dayton Physician LLC - Englewood

Dayton, Ohio, 45415, United States

[email protected] / 937-528-2900

Status: Recruiting

Delaware Health Center-Grady Cancer Center

Delaware, Ohio, 43015, United States

[email protected] / 614-788-3860

Status: Recruiting

Grady Memorial Hospital

Delaware, Ohio, 43015, United States

[email protected] / 614-788-3860

Status: Recruiting

Columbus Oncology and Hematology Associates

Dublin, Ohio, 43016, United States

[email protected] / 614-788-3860

Status: Recruiting

Dublin Methodist Hospital

Dublin, Ohio, 43016, United States

[email protected] / 614-788-3860

Status: Recruiting

Kettering Medical Center

Kettering, Ohio, 45429, United States

[email protected] / 937-528-2900

Status: Recruiting

Fairfield Medical Center

Lancaster, Ohio, 43130, United States

[email protected] / 614-488-2745

Status: Recruiting

OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903, United States

[email protected] / 614-788-3860

Status: Recruiting

OhioHealth Marion General Hospital

Marion, Ohio, 43302, United States

[email protected] / 614-788-3860

Status: Recruiting

Memorial Hospital

Marysville, Ohio, 43040, United States

[email protected] / 614-488-2745

Status: Recruiting

UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060, United States

[email protected] / 800-641-2422

Status: Recruiting

Knox Community Hospital

Mount Vernon, Ohio, 43050, United States

[email protected] / 614-488-2745

Status: Recruiting

Licking Memorial Hospital

Newark, Ohio, 43055, United States

[email protected] / 614-488-2745

Status: Recruiting

Mercy Health - Perrysburg Hospital

Perrysburg, Ohio, 43551, United States

[email protected] / 614-488-2745

Status: Recruiting

Southern Ohio Medical Center

Portsmouth, Ohio, 45662, United States

[email protected] / 614-488-2745

Status: Recruiting

Springfield Regional Cancer Center

Springfield, Ohio, 45504, United States

[email protected] / 614-488-2745

Status: Recruiting

Springfield Regional Medical Center

Springfield, Ohio, 45504, United States

[email protected] / 614-488-2745

Status: Recruiting

Mercy Health - Saint Anne Hospital

Toledo, Ohio, 43623, United States

[email protected] / 614-488-2745

Status: Recruiting

OhioHealth Westerville Medical Campus/Westerville Cancer Center

Westerville, Ohio, 43082, United States

[email protected] / 610-788-3860

Status: Recruiting

Genesis Healthcare System Cancer Care Center

Zanesville, Ohio, 43701, United States

[email protected] / 614-488-2745

Status: Recruiting

Saint Ann's Hospital

Westerville, Ohio, 43081, United States

[email protected] / 614-488-2745

Status: Recruiting

UH Seidman Cancer Center at UH Avon Health Center

Avon, Ohio, 44011, United States

No email / 800-641-2422

Status: Recruiting

UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122, United States

[email protected] / 800-641-2422

Status: Recruiting

Strecker Cancer Center-Belpre

Belpre, Ohio, 45714, United States

[email protected] / 614-488-2745

Status: Recruiting

Aultman Health Foundation

Canton, Ohio, 44710, United States

[email protected] / 330-363-7274

Status: Recruiting

Adena Regional Medical Center

Chillicothe, Ohio, 45601, United States

[email protected] / 877-779-7585

Status: Recruiting

Case Western Reserve University

Cleveland, Ohio, 44106, United States

[email protected] / 800-641-2422

Status: Recruiting

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

[email protected] / 405-271-8777

Status: Recruiting

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914, United States

[email protected] / 406-969-6060

Status: Recruiting

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045, United States

[email protected] / 503-215-2614

Status: Recruiting

Providence Portland Medical Center

Portland, Oregon, 97213, United States

[email protected] / 503-215-2614

Status: Recruiting

Providence Saint Vincent Medical Center

Portland, Oregon, 97225, United States

[email protected] / 503-215-2614

Status: Recruiting

Providence Newberg Medical Center

Newberg, Oregon, 97132, United States

[email protected] / 503-215-2614

Status: Recruiting

UPMC Cancer Centers - Arnold Palmer Pavilion

Greensburg, Pennsylvania, 15601, United States

No email / 724-838-1900

Status: Recruiting

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103, United States

[email protected] / 610-402-9543

Status: Recruiting

UPMC Altoona

Altoona, Pennsylvania, 16601, United States

[email protected] / No phone

Status: Recruiting

Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017, United States

[email protected] / 610-402-9543

Status: Recruiting

Bryn Mawr Hospital

Bryn Mawr, Pennsylvania, 19010, United States

[email protected] / 484-476-2649

Status: Recruiting

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301, United States

[email protected] / 610-402-9543

Status: Recruiting

UPMC Hillman Cancer Center Erie

Erie, Pennsylvania, 16505, United States

[email protected] / 412-389-5208

Status: Recruiting

Lehigh Valley Hospital-Hazleton

Hazleton, Pennsylvania, 18201, United States

[email protected] / 610-402-9543

Status: Recruiting

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

Mechanicsburg, Pennsylvania, 17050, United States

[email protected] / 412-389-5208

Status: Recruiting

Riddle Memorial Hospital

Media, Pennsylvania, 19063, United States

[email protected] / 484-476-2649

Status: Recruiting

UPMC Hillman Cancer Center - Monroeville

Monroeville, Pennsylvania, 15146, United States

[email protected] / 412-389-5208

Status: Recruiting

Paoli Memorial Hospital

Paoli, Pennsylvania, 19301, United States

[email protected] / 484-476-2649

Status: Recruiting

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

[email protected] / 215-600-9151

Status: Recruiting

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States

No email / 412-647-8073

Status: Recruiting

UPMC-Passavant Hospital

Pittsburgh, Pennsylvania, 15237, United States

No email / 412-367-6454

Status: Recruiting

Lankenau Medical Center

Wynnewood, Pennsylvania, 19096, United States

[email protected] / 484-476-2649

Status: Recruiting

Women and Infants Hospital

Providence, Rhode Island, 02905, United States

No email / 401-274-1122

Status: Recruiting

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134, United States

[email protected] / 605-312-3320

Status: Recruiting

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104, United States

[email protected] / 605-312-3320

Status: Recruiting

Rapid City Regional Hospital

Rapid City, South Dakota, 57701, United States

No email / No phone

Status: Active, not recruiting

M D Anderson Cancer Center

Houston, Texas, 77030, United States

[email protected] / 877-632-6789

Status: Recruiting

Inova Fairfax Hospital

Falls Church, Virginia, 22042, United States

[email protected] / 703-208-6650

Status: Recruiting

Virginia Cancer Institute

Richmond, Virginia, 23229, United States

[email protected] / 804-287-3000

Status: Recruiting

VCU Massey Cancer Center at Stony Point

Richmond, Virginia, 23235, United States

[email protected] / No phone

Status: Recruiting

Virginia Commonwealth University/Massey Cancer Center

Richmond, Virginia, 23298, United States

[email protected] / No phone

Status: Recruiting

Carilion Roanoke Memorial Hospital

Roanoke, Virginia, 24033, United States

No email / 540-985-8510

Status: Recruiting

VCU Community Memorial Health Center

South Hill, Virginia, 23970, United States

[email protected] / No phone

Status: Recruiting

Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States

[email protected] / 703-720-5210

Status: Recruiting

University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States

[email protected] / 434-243-6303

Status: Recruiting

Valley Medical Center

Renton, Washington, 98055, United States

[email protected] / 425-228-3440

Status: Recruiting

Swedish Medical Center-First Hill

Seattle, Washington, 98122, United States

[email protected] / 206-215-2343

Status: Recruiting

North Star Lodge Cancer Center at Yakima Valley Memorial Hospital

Yakima, Washington, 98902, United States

[email protected] / 509-574-3535

Status: Recruiting

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026, United States

[email protected] / 206-215-2343

Status: Recruiting

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029, United States

[email protected] / 206-215-2343

Status: Recruiting

Aurora Saint Luke's South Shore

Cudahy, Wisconsin, 53110, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Health Care Germantown Health Center

Germantown, Wisconsin, 53022, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Cancer Care-Grafton

Grafton, Wisconsin, 53024, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora BayCare Medical Center

Green Bay, Wisconsin, 54311, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Cancer Care-Kenosha South

Kenosha, Wisconsin, 53142, United States

[email protected] / 414-302-2304

Status: Recruiting

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601, United States

[email protected] / 608-775-2385

Status: Recruiting

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

Madison, Wisconsin, 53718, United States

[email protected] / 800-622-8922

Status: Recruiting

University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States

[email protected] / 800-622-8922

Status: Recruiting

Aurora Bay Area Medical Group-Marinette

Marinette, Wisconsin, 54143, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Cancer Care-Milwaukee

Milwaukee, Wisconsin, 53209, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Saint Luke's Medical Center

Milwaukee, Wisconsin, 53215, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Sinai Medical Center

Milwaukee, Wisconsin, 53233, United States

[email protected] / 414-302-2304

Status: Recruiting

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, 54904, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Cancer Care-Racine

Racine, Wisconsin, 53406, United States

[email protected] / 414-302-2304

Status: Recruiting

Vince Lombardi Cancer Clinic-Sheboygan

Sheboygan, Wisconsin, 53081, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Medical Center in Summit

Summit, Wisconsin, 53066, United States

[email protected] / 414-302-2304

Status: Recruiting

Vince Lombardi Cancer Clinic-Two Rivers

Two Rivers, Wisconsin, 54241, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora Cancer Care-Milwaukee West

Wauwatosa, Wisconsin, 53226, United States

[email protected] / 414-302-2304

Status: Recruiting

Aurora West Allis Medical Center

West Allis, Wisconsin, 53227, United States

[email protected] / 414-302-2304

Status: Recruiting

Duluth Clinic Ashland

Ashland, Wisconsin, 54806, United States

[email protected] / 218-786-3308

Status: Recruiting

Aurora Cancer Care-Southern Lakes VLCC

Burlington, Wisconsin, 53105, United States

[email protected] / 414-302-2304

Status: Recruiting

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: Ipatasertib (RG7440, GDC-0068)

Overview

Mechanism of Action

Efficacy

Safety

Further Reading

More Resources

Show News & AI Analysis

HealthScout AI Analysis

Eligibility

Show Criteria

Sites (207)

Centro Comprensivo de Cancer de UPR

Puerto Rico Hematology Oncology Group

University of South Alabama Mitchell Cancer Institute

University of Alabama at Birmingham Cancer Center

Alaska Women's Cancer Care

Kingman Regional Medical Center

Stanford Cancer Institute Palo Alto

Saint John's Cancer Institute

PCR Oncology

Cedars Sinai Medical Center

Saint Joseph Hospital - Orange

The Angeles Clinic and Research Institute - West Los Angeles Office

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Mayo Clinic in Florida

University of Miami Miller School of Medicine-Sylvester Cancer Center

UM Sylvester Comprehensive Cancer Center at Kendall

UM Sylvester Comprehensive Cancer Center at Plantation

UM Sylvester Comprehensive Cancer Center at Aventura

UM Sylvester Comprehensive Cancer Center at Coral Gables

Kootenai Health - Coeur d'Alene

Saint Alphonsus Cancer Care Center-Boise

Saint Luke's Cancer Institute - Boise

Saint Alphonsus Cancer Care Center-Caldwell

Saint Luke's Cancer Institute - Fruitland

Saint Luke's Cancer Institute - Meridian

Saint Alphonsus Cancer Care Center-Nampa

Saint Luke's Cancer Institute - Nampa

Kootenai Clinic Cancer Services - Post Falls

Kootenai Clinic Cancer Services - Sandpoint

Saint Luke's Cancer Institute - Twin Falls

Advocate Good Shepherd Hospital

Advocate Illinois Masonic Medical Center

AMG Crystal Lake - Oncology

Carle at The Riverfront

Advocate Good Samaritan Hospital

Carle Physician Group-Effingham

Advocate Sherman Hospital

Advocate South Suburban Hospital

AMG Libertyville - Oncology

Condell Memorial Hospital

Carle Physician Group-Mattoon/Charleston

UC Comprehensive Cancer Center at Silver Cross

Advocate Christ Medical Center

University of Chicago Medicine-Orland Park

Advocate Lutheran General Hospital

Carle Cancer Center

John H Stroger Jr Hospital of Cook County

University of Chicago Comprehensive Cancer Center

Mercy Medical Center - Des Moines

UI Health Care Mission Cancer and Blood - Waukee Clinic

UI Health Care Mission Cancer and Blood - Ankeny Clinic

UI Health Care Mission Cancer and Blood - Des Moines Clinic

University of Kentucky/Markey Cancer Center

Harold Alfond Center for Cancer Care

Lafayette Family Cancer Center-EMMC

MaineHealth Maine Medical Center- Scarborough

UPMC Western Maryland

University of Maryland/Greenebaum Cancer Center

National Institutes of Health Clinical Center

Tufts Medical Center

Trinity Health IHA Medical Group Hematology Oncology - Canton

Trinity Health Medical Center - Canton

Chelsea Hospital